Walsh W, Usman A. 2001. Metallothionein Dysfunction in Children Diagnosed with Autism Spectrum Disorders. Poster: American Psychiatric Accosciation Annual Meeting, May 10, 2001. Pfeiffer Treatment Center, IL.

Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. 2004. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 9(4):358-70.

Warren Grant Magnuson Clinical Center, National Institutes of Health. 2004. Preparing for Transfusion Therapy. Online: http://www.healthfinder.gov/orgs/HR0022.htm.

Warren RP, Margaretten NC, Pace NC, Foster A. 1986. Immune abnormalities in patients with autism. J Autism Dev Disord 16(2):189-97.

Warren RP, Foster A, Margaretten NC. 1987. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 26(3):333-5.

Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, White E. 1991. Increased frequency of the null allele at the complement C4b locus in autism. Clin Exp Immunol 83(3):438-40.

Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, DeWitt CW, McCullough M. 1992. Possible association of the extended MHC haplotype B44-SC30-DR4 with autism. Immunogenetics 36(4):203-7.

Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR. 1996. Strong association of the third hypervariable region of HLA-DR beta 1 with autism. J Neuroimmunol 67(2):97-102.

Wassink TH, Piven J, Vieland VJ, Huang J, Swiderski RE, Pietila J, Braun T, Beck G, Folstein SE, Haines JL, Sheffield VC. 2001. Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet 105(5):406-13.

Watson JC, Redd SC, Rhodes PH, Hadler SC. 1998. The interruption of transmission of indigenous measles in the United States during 1993. Pediatr Infect Dis J 17(5):363-6; discussion 366-7.

Weed DL, Hursting SD. 1998. Biologic plausibility in causal inference: current method and practice. Am J Epidemiol 147(5):415-25.

Wentz P.W. 2000. Chelation therapy: conventional treatments. Advance/Laboratory. Available at http://www.advanceforAL.com.

Werner E, Dawson G, Munson J, Osterling J. In Press. Variation in early developmental course in autism and its relation with behavioral outcome at 3-4 years of age. J Autism Dev Disorder.

Wilson GS. 1967. The Hazards of Immunization. New York: The Athlone Press. Pp. 75-84.

Wilson K. 2004. Presentation to the Immunization Safety Review Committee. Washington, DC.

Wilson K, Mills E, Ross C, McGowan J, Jadad A. 2003. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 157(7):628-34.

Wing L, Potter D. 2002. The epidemiology of autistic spectrum disorders: is the prevalence rising? Mental Ret Dev Disabil Res Rev 8:151-61.


Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. 2003. Prevalence of autism in a US metropolitan area. JAMA 289(1):49-55.


Zimmerman AW. 2000. Commentary: immunological treatments for autism: in search of reasons for promising approaches. J Autism Dev Disord 30(5):481-4.

Zoghbi HY. 2003. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302(5646):826-30.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement